Roche Experimenting With New Pricing Models In Oncology
Cancer drug prices are unsustainable and creative approaches are needed, Roche’s O’Day says. The firm’s moves into emerging markets are a lab for new methods, he said, though the real test will come as the more expensive drugs are used in combination.
You may also be interested in...
“We should not discourage innovation right now,” Pfizer’s Group President of Vaccines, Oncology and Consumer Healthcare Albert Bourla said during a media briefing at the company headquarters.
Lilly has been considering ways to gather the kind of data that would enable it to price oncology drugs by tumor type, VP Oncology Newton Crenshaw says.
U.S. FDA approval is fifth indication for Roche/Genentech’s Avastin. The number of cases in the U.S. is low and set to decline with better prevention, but disease is still considered a major global health problem.